May 31, 2015 | Oramed Pharmaceuticals, an Israeli company developing an insulin pill for diabetics, announced this week that it submitted a study protocol for its Phase IIb trials with the US Food & Drug Administration (FDA). The drug, tentatively named ORMD-0801 is an orally ingestible insulin capsule for the control and treatment of diabetes. It’s expected that the pill will change the face of current diabetes treatments. Oramed was founded in 2006 and is headquartered in Jerusalem.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments